Biotechnology company · ALNY

Alnylam Pharmaceuticals
clinical trial
pipeline

Registry checked

Published

Nucresiran is linked to 2 distinct active studies: 2 recruiting. Vutrisiran is linked to 2 distinct active studies: 1 active but not recruiting, 1 enrolling by invitation.

Phase 2 study NCT07463846 in Obesity lists estimated primary completion on 28 April 2027. Phase 2 study NCT07465224 in Type 2 Diabetes Mellitus (T2DM) lists estimated primary completion on 28 May 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

26active trials
as lead sponsor
  • Phase 17
  • Phase 28
  • Phase 35
  • Phase 40
  • Phase not recorded6

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

32 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved earlier by 99 days

2029-04-20 (estimated)2029-01-11 (estimated)
20 Apr 202911 Jan 2029

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785 · ClinicalTrials.gov
Recorded by ComplyRx
20 Oct 2026
Registry last updated
20 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-161010021
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200100011
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
Type totals1110032 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Nucresiran

Canonical investigational asset

2
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
hATTR-PN · Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy · Transthyretin Amyloidosis With Cardiomyopathy
Next primary completion
Not reported
Open drug

Vutrisiran

AMVUTTRA

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Next primary completion
Not reported
Open drug

ALN-4324

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Obese or Overweight Healthy Volunteers · Type 2 Diabetes Mellitus (T2DM)
Next primary completion
28 May 2027 · estimated
Open drug

ALN-6400

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Heavy Menstrual Bleeding (HMB) · Hereditary Hemorrhagic Telangiectasia · Von Willebrand Disease (VWD)
Next primary completion
30 June 2027 · estimated
Open drug

ALN-APP

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Cerebral Amyloid Angiopathy · Early-Onset Alzheimer Disease
Next primary completion
09 August 2027 · estimated
Open drug

Zilebesiran

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
High Cardiovascular Risk · High Risk Cardiovascular Disease · Hypertension
Next primary completion
Not reported
Open drug

18 of 26 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 18 of 26 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Alnylam Pharmaceuticals trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study to Evaluate ALN-2232 in Participants With Obesity
ALN-2232

NCT07463846

Phase 2 · Recruiting

Trial source and qualifications

A Study to Evaluate ALN-2232 in Participants With Obesity

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 02 Mar 2026 · actual
    Primary completion: 28 Apr 2027 · estimated
    Study completion: 28 Apr 2028 · estimated

    2021202220232024202520262027202820292030
    A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
    ALN-4324

    NCT07465224

    Phase 2 · Recruiting

    Trial source and qualifications

    A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 15 Jan 2026 · actual
      Primary completion: 28 May 2027 · estimated
      Study completion: 28 May 2027 · estimated

      2021202220232024202520262027202820292030
      HMBeacon
      ALN-6400

      NCT07575308

      Phase 2 · Recruiting

      Trial source and qualifications

      HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

      1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      Up to three verified eligible observations in the bounded history window.

      • status flip · Recorded 2026-08-12 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 30 Jul 2026 · actual
      Primary completion: 30 Jun 2027 · estimated
      Study completion: 30 Aug 2029 · estimated

      2021202220232024202520262027202820292030
      cAPPricorn-1
      ALN-APP

      NCT06393712

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

      • enrollment change · Recorded 2026-09-03 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
      • status flip · Recorded 2026-09-03 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 17 May 2024 · actual
      Primary completion: 09 Aug 2027 · estimated
      Study completion: 14 Dec 2029 · estimated

      2021202220232024202520262027202820292030
      A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
      ALN-4324

      NCT06845202

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

      5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      5 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 03 Mar 2025 · actual
        Primary completion: 31 Aug 2027 · estimated
        Study completion: 31 Aug 2027 · estimated

        2021202220232024202520262027202820292030
        TRITON-PN
        Nucresiran

        NCT07223203

        Phase 3 · Recruiting

        Trial source and qualifications

        TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

        Duration ends at independently recorded study completion. Source date qualifications: end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        End clipped at the display horizon.

        1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 03 Feb 2026 · actual
          Primary completion: 27 Dec 2027 · estimated
          Study completion: 12 Jun 2031 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 12 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 1 actual primary completions, 0 untyped primary completions, 0 past estimates, 0 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          6

          active trials in Cardiovascular

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Cardiovascular6 trials
          • Neurology5 trials
          • Metabolic/Endocrine/Nutrition4 trials
          • Genetic & Rare Disease1 trials
          • Haematology1 trials
          • Oncology1 trials
          • Ophthalmology1 trials
          • Unmapped5 trials
          • Healthy volunteers2 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies

          No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 84 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Alnylam Pharmaceuticals. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          84 distinct registry candidates produced 84 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          71 scoped records have indexed enrichment and 13 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-10-31T23:39:52.472Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 869da2c129f25d76babd7e3de4aed42e1ff5bdd15ea546ef7e8b7031bc97c266.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 84 mapped lead-sponsored clinical studies across all statuses. 71 have indexed enrichment, 13 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.